• Amir Qaseem, Vincenza Snow, Paul Shekelle, Donald E Casey, J Thomas Cross, Douglas K Owens, Clinical Efficacy Assessment Subcommittee of the American College of Physicians, Paul Dallas, Nancy C Dolan, Mary Ann Forciea, Lakshmi Halasyamani, and Robert H Hopkins.
• American College of Physicians, Philadelphia, Pennsylvania 19106, USA. aqaseem@acponline.org
• Ann. Intern. Med. 2008 Jan 15;148(2):141-6.

AbstractRECOMMENDATION 1: In patients with serious illness at the end of life, clinicians should regularly assess patients for pain, dyspnea, and depression. (Grade: strong recommendation, moderate quality of evidence.) RECOMMENDATION 2: In patients with serious illness at the end of life, clinicians should use therapies of proven effectiveness to manage pain. For patients with cancer, this includes nonsteroidal anti-inflammatory drugs, opioids, and bisphosphonates. (Grade: strong recommendation, moderate quality of evidence.) RECOMMENDATION 3: In patients with serious illness at the end of life, clinicians should use therapies of proven effectiveness to manage dyspnea, which include opioids in patients with unrelieved dyspnea and oxygen for short-term relief of hypoxemia. (Grade: strong recommendation, moderate quality of evidence.) RECOMMENDATION 4: In patients with serious illness at the end of life, clinicians should use therapies of proven effectiveness to manage depression. For patients with cancer, this includes tricyclic antidepressants, selective serotonin reuptake inhibitors, or psychosocial intervention. (Grade: strong recommendation, moderate quality of evidence.) RECOMMENDATION 5: Clinicians should ensure that advance care planning, including completion of advance directives, occurs for all patients with serious illness. (Grade: strong recommendation, low quality of evidence.).

18 keywords...

hide…